Stanbery Hannah
The general prognosis for women with advanced ovarian cancer is still dismal, despite advancements in surgery and chemotherapy. Although platinum-based chemotherapy has an initial response rate of roughly 60–80%, the majority of patients will have a recurrence and pass away from the disease. However, a precision medicine approach focused on DNA repair has lately given rise to genuine optimism about increasing survival. Many individuals with BRCA germlinedeficient and/or platinum-sensitive epithelial ovarian malignancies have seen lifechanging effects as a result of the clinical development of PARP inhibitors. Patients' prognosis could also be improved by intraperitoneal chemotherapeutic methods and antiangiogenic medications. Additionally, developing immunotherapeutic possibilities could benefit patient results.
The effectiveness of immunotherapy in treating ovarian cancer is still limited; however, evaluating sensitive/resistant target treatment subpopulations based on tumour biomarker stratification may increase the predictability of response to immunotherapy. These markers include PD-L1, tumor-infiltrating cells, homologous recombination deficit, tumour mutation burden, and intratumoral heterogeneity of neoantigens. The use of these indicators to choose the best candidates for treatment of ovarian cancer is one of the next prospects in the field. The role of immunotherapy in ovarian cancer is discussed in this paper, along with innovative treatments and research designs including tumour biomarkers that improve the chances of immunotherapy effectiveness in ovarian cancer.
KeywordsOvarian cancer; Poly-(ADP)-Ribose Polymerase; PARP; Synthetic lethality; Platinum Chemotherapy; Ovarian cancer; Immunotherapy; Biomarker
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi